CVS Health (1CVS) Stock Forecast & Price Target

5 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1CVS Analyst Ratings

Strong Buy

18 Buy

1 Hold

0 Sell

Based on 19 analysts giving stock ratings to

CVS

Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1CVS Stock 12 Month Forecast

Average Price Target

€99.11

▲(4.66% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for CVS Health in the last 3 months. The average price target is €99.11 with a high forecast of €108.32 and a low forecast of €89.26. The average price target represents a 4.66% change from the last price of €94.70.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"59":"€59","84":"€84","109":"€109","71.5":"€71.5","96.5":"€96.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":108.32255125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€108.32</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":99.10943320684211,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€99.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":89.25778223,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€89.26</span>\n  </div></div>","useHTML":true}}],"tickPositions":[59,71.5,84,96.5,109],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,84,85.87096548076923,87.74193096153846,89.61289644230769,91.48386192307693,93.35482740384616,95.22579288461539,97.09675836538462,98.96772384615385,100.83868932692309,102.70965480769232,104.58062028846155,106.45158576923077,{"y":108.32255125,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,84,85.16226409283401,86.32452818566802,87.48679227850202,88.64905637133603,89.81132046417004,90.97358455700405,92.13584864983807,93.29811274267207,94.46037683550608,95.62264092834009,96.7849050211741,97.9471691140081,{"y":99.10943320684211,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,84,84.40444478692308,84.80888957384616,85.21333436076924,85.6177791476923,86.02222393461538,86.42666872153846,86.83111350846154,87.23555829538462,87.6400030823077,88.04444786923077,88.44889265615384,88.85333744307692,{"y":89.25778223,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":60.811,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.71,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.15,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.879,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.362,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.377,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.736,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.549,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.666,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.544,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.187,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.5,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€108.32

Average Price Target€99.11

Lowest Price Target€89.26

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Allen Lutz

Bank of America Securities

€909.91→€103.99

Buy

9.81%

Upside

Reiterated

09/15/26

Analysts Offer Insights on Healthcare Companies: Benitec Biopharma (NASDAQ: BNTC), CVS Health (NYSE: CVS) and BioNTech SE (NASDAQ: BNTX)

Stephen Baxter

Wells Fargo

€106.59

Buy

12.55%

Upside

Reiterated

09/15/26

Analysts Offer Insights on Healthcare Companies: CVS Health (NYSE: CVS), Ascendis Pharma (NASDAQ: ASND) and BridgeBio Oncology Therapeutics (NASDAQ: BBOT)

Lance Wilkes

Bernstein

€91.86

Buy

-3.00%

Downside

Assigned

09/09/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Stryker (NYSE: SYK), CVS Health (NYSE: CVS) and Biogen (NASDAQ: BIIB)

Kevin Caliendo

UBS

€109.19→€102.26

Buy

7.98%

Upside

Assigned

09/03/26

CVS Health price target lowered to $118 from $126 at UBSCVS Health price target lowered to $118 from $126 at UBS

Brian Tanquilut

Jefferies

€103.99

Buy

9.81%

Upside

Reiterated

08/31/26

CVS Health remains top large cap pick in healthcare services at JefferiesCVS Health remains top large cap pick in healthcare services at Jefferies

Charles Rhyee

TD Cowen

€95.32

Buy

0.66%

Upside

Reiterated

08/26/26

Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (NASDAQ: SYRE) and CVS Health (NYSE: CVS)

Jessica Tassan

Piper Sandler

€97.92

Buy

3.40%

Upside

Reiterated

08/26/26

Piper Sandler Remains a Buy on CVS Health (CVS)

Steven Silver

Argus Research

€90.12→€98.79

Buy

4.32%

Upside

Reiterated

08/18/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and CVS Health (NYSE: CVS)

Lisa Gill

J.P. Morgan

€96.19→€102.26

Buy

7.98%

Upside

Reiterated

08/12/26

J.P. Morgan Remains a Buy on CVS Health (CVS)

Erin Wright

Morgan Stanley

€96.19

Buy

1.57%

Upside

Assigned

08/10/26

Morgan Stanley Keeps Their Buy Rating on CVS Health (CVS)

David S Macdonald

Truist Financial

€102.26

Buy

7.98%

Upside

Reiterated

08/06/26

Analysts Offer Insights on Healthcare Companies: Agilon Health (NYSE: AGL), CVS Health (NYSE: CVS) and Sarepta Therapeutics (NASDAQ: SRPT)

Ben Hendrix

RBC Capital

€97.92

Buy

3.40%

Upside

Reiterated

08/06/26

RBC Capital Sticks to Their Buy Rating for CVS Health (CVS)

Elizabeth Anderson CFA

Evercore ISI

€112.66→€108.32

Buy

14.38%

Upside

Reiterated

08/06/26

Analysts Are Bullish on These Healthcare Stocks: Myomo (MYO), CVS Health (CVS)

Michael Ha

Robert W. Baird

€81.46→€92.72

Buy

-2.09%

Downside

Reiterated

08/06/26

CVS Health price target raised to $107 from $94 at BairdCVS Health price target raised to $107 from $94 at Baird

Andrew Mok CFA

Barclays

€91.86→€93.59

Buy

-1.17%

Downside

Reiterated

08/06/26

Barclays Sticks to Its Buy Rating for CVS Health (CVS)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Allen Lutz

Bank of America Securities

€909.91→€103.99

Buy

9.81%

Upside

Reiterated

09/15/26

Analysts Offer Insights on Healthcare Companies: Benitec Biopharma (NASDAQ: BNTC), CVS Health (NYSE: CVS) and BioNTech SE (NASDAQ: BNTX)

Stephen Baxter

Wells Fargo

€106.59

Buy

12.55%

Upside

Reiterated

09/15/26

Analysts Offer Insights on Healthcare Companies: CVS Health (NYSE: CVS), Ascendis Pharma (NASDAQ: ASND) and BridgeBio Oncology Therapeutics (NASDAQ: BBOT)

Lance Wilkes

Bernstein

€91.86

Buy

-3.00%

Downside

Assigned

09/09/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Stryker (NYSE: SYK), CVS Health (NYSE: CVS) and Biogen (NASDAQ: BIIB)

Kevin Caliendo

UBS

€109.19→€102.26

Buy

7.98%

Upside

Assigned

09/03/26

CVS Health price target lowered to $118 from $126 at UBSCVS Health price target lowered to $118 from $126 at UBS

Brian Tanquilut

Jefferies

€103.99

Buy

9.81%

Upside

Reiterated

08/31/26

CVS Health remains top large cap pick in healthcare services at JefferiesCVS Health remains top large cap pick in healthcare services at Jefferies

Charles Rhyee

TD Cowen

€95.32

Buy

0.66%

Upside

Reiterated

08/26/26

Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (NASDAQ: SYRE) and CVS Health (NYSE: CVS)

Jessica Tassan

Piper Sandler

€97.92

Buy

3.40%

Upside

Reiterated

08/26/26

Piper Sandler Remains a Buy on CVS Health (CVS)

Steven Silver

Argus Research

€90.12→€98.79

Buy

4.32%

Upside

Reiterated

08/18/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and CVS Health (NYSE: CVS)

Lisa Gill

J.P. Morgan

€96.19→€102.26

Buy

7.98%

Upside

Reiterated

08/12/26

J.P. Morgan Remains a Buy on CVS Health (CVS)

Erin Wright

Morgan Stanley

€96.19

Buy

1.57%

Upside

Assigned

08/10/26

Morgan Stanley Keeps Their Buy Rating on CVS Health (CVS)

David S Macdonald

Truist Financial

€102.26

Buy

7.98%

Upside

Reiterated

08/06/26

Analysts Offer Insights on Healthcare Companies: Agilon Health (NYSE: AGL), CVS Health (NYSE: CVS) and Sarepta Therapeutics (NASDAQ: SRPT)

Ben Hendrix

RBC Capital

€97.92

Buy

3.40%

Upside

Reiterated

08/06/26

RBC Capital Sticks to Their Buy Rating for CVS Health (CVS)

Elizabeth Anderson CFA

Evercore ISI

€112.66→€108.32

Buy

14.38%

Upside

Reiterated

08/06/26

Analysts Are Bullish on These Healthcare Stocks: Myomo (MYO), CVS Health (CVS)

Michael Ha

Robert W. Baird

€81.46→€92.72

Buy

-2.09%

Downside

Reiterated

08/06/26

CVS Health price target raised to $107 from $94 at BairdCVS Health price target raised to $107 from $94 at Baird

Andrew Mok CFA

Barclays

€91.86→€93.59

Buy

-1.17%

Downside

Reiterated

08/06/26

Barclays Sticks to Its Buy Rating for CVS Health (CVS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ARWRArrowhead Pharmaceuticals

ZYMEZymeworks

TEVATeva Pharmaceutical

AHCOAdaptHealth

PTGXProtagonist Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering CVS Health

3 Months

Stephen BaxterWells Fargo

Success Rate

15/20 ratings generated profit

Average Return

+12.16%

Copying Stephen Baxter's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +12.16% per trade.

1 Year

Stephen BaxterWells Fargo

Success Rate

18/20 ratings generated profit

Average Return

+28.40%

Copying Stephen Baxter's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +28.40% per trade.

2 Years

Stephen BaxterWells Fargo

Success Rate

18/20 ratings generated profit

Average Return

+39.48%

Copying Stephen Baxter's trades and holding each position for 2 Years would result in 90.00% of your transactions generating a profit, with an average return of +39.48% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1CVS Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1CVS has received 35 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 1CVS average Analyst price target in the past 3 months is 99.11.

Each month's total comprises the sum of three months' worth of ratings.

1CVS Financial Forecast

1CVS Earnings Forecast

Next quarter’s earnings estimate for 1CVS is €1.42 with a range of €1.27 to €1.68. The previous quarter’s EPS was €2.24. 1CVS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1CVS has Performed in-line its overall industry.

1CVS Sales Forecast

Next quarter’s sales forecast for 1CVS is €90.61B with a range of €88.75B to €94.18B. The previous quarter’s sales results were €92.01B. 1CVS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1CVS has Performed in-line its overall industry.

1CVS Stock Forecast FAQ

What is IT:1CVS’s average 12-month price target, according to analysts?

Based on analyst ratings, CVS Health Corp’s 12-month average price target is 99.11.

What is IT:1CVS’s upside potential, based on the analysts’ average price target?

CVS Health Corp has 4.66% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CVS Health Corp a Buy, Sell or Hold?

CVS Health Corp has a consensus rating of Strong Buy, which is based on 18 buy ratings, 1 hold ratings and 0 sell ratings.

What is CVS Health Corp’s share price target?

The average share price target for CVS Health Corp is 99.11. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €108.32 ,and the lowest forecast is €89.26. The average share price target represents 4.66% Increase from the current price of €94.7.

What do analysts say about CVS Health Corp?

CVS Health Corp’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of CVS Health Corp?

To buy shares of IT:1CVS, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

CVS Health (1CVS) Stock Forecast & Price Target

1CVS Analyst Ratings

1CVS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering CVS Health

1CVS Analyst Recommendation Trends

1CVS Financial Forecast

1CVS Earnings Forecast

1CVS Sales Forecast

1CVS Stock Forecast FAQ

Detailed List of Analyst Forecasts